Characteristics of patients
. | Patients with AML/MDS, N = 22, 1.34% . | Patients without AML/MDS, N = 1616, 98.66% . | P . |
|---|---|---|---|
| Sex (male) | 8 (36.36) | 934 (57.80) | .0434 |
| Mean age at registration, y (SD) | 70.90 (7.90) | 65.33 (12.71) | .0036 |
| Median time from diagnosis of PV to registration, y (range) | 7.0 (0.68-18.48) | 3.45 (0-39.53) | .0067 |
| Hematologic parameters at diagnosis of PV (%) | |||
| Clinically palpable splenomegaly | 11 (50.00) | 651 (40.28) | .3563 |
| Platelet count > 400 × 109/L | 14 (63.64) | 985 (60.95) | .7977 |
| WBC count > 12 × 109/L | 13 (59.09) | 650 (40.22) | .0733 |
| Clinical and laboratory parameters at registration | |||
| Splenomegaly (%) | 12 (54.55) | 720 (44.55) | .3492 |
| PCV, L/L (SD) | 0.45 (0.06) | 0.47 (0.06) | .1051 |
| Platelet count, × 109/L (SD) | 319 (177) | 400 (208) | .0695 |
| WBC count, × 109/L (SD) | 12.70 (7.42) | 10.89 (8.64) | .3490 |
| Cholesterol level, mg/dL (SD) | 157 (58) | 188 (45) | .0157 |
| Treatment at registration (%) | |||
| Phlebotomy | 13 (59.09) | 1027 (63.55) | .6660 |
| P32 | 3 (13.64) | 41 (2.54) | .0014 |
| Hydroxyurea | 10 (45.45) | 783 (48.45) | .7798 |
| Busulphan | 4 (18.18) | 57 (3.53) | .0003 |
| Chlorambucil | 0 (0.00) | 5 (0.31) | .7939 |
| Pipobroman | 4 (18.18) | 102 (6.31) | .0246 |
| Interferon | 1 (4.55) | 63 (3.90) | .8764 |
| Groups of treatment at registration (%) | |||
| No treatment, phlebotomy only, or interferon only | 5 (22.73) | 664 (41.09) | .0818 |
| Hydroxyurea as only cytoreductive drug | 6 (27.27) | 736 (45.54) | .0873 |
| Any other cytoreductive drug, alone or in combination | 11 (50.00) | 216 (13.37) | < .0001 |
| More than 1 cytoreductive drug | 4 (18.18) | 54 (3.34) | .0002 |
| Event at follow-up (%) | |||
| Thrombosis | 5 (22.73) | 226 (13.99) | .2419 |
| Hemorrhage | 4 (18.18) | 117 (7.24) | .0513 |
. | Patients with AML/MDS, N = 22, 1.34% . | Patients without AML/MDS, N = 1616, 98.66% . | P . |
|---|---|---|---|
| Sex (male) | 8 (36.36) | 934 (57.80) | .0434 |
| Mean age at registration, y (SD) | 70.90 (7.90) | 65.33 (12.71) | .0036 |
| Median time from diagnosis of PV to registration, y (range) | 7.0 (0.68-18.48) | 3.45 (0-39.53) | .0067 |
| Hematologic parameters at diagnosis of PV (%) | |||
| Clinically palpable splenomegaly | 11 (50.00) | 651 (40.28) | .3563 |
| Platelet count > 400 × 109/L | 14 (63.64) | 985 (60.95) | .7977 |
| WBC count > 12 × 109/L | 13 (59.09) | 650 (40.22) | .0733 |
| Clinical and laboratory parameters at registration | |||
| Splenomegaly (%) | 12 (54.55) | 720 (44.55) | .3492 |
| PCV, L/L (SD) | 0.45 (0.06) | 0.47 (0.06) | .1051 |
| Platelet count, × 109/L (SD) | 319 (177) | 400 (208) | .0695 |
| WBC count, × 109/L (SD) | 12.70 (7.42) | 10.89 (8.64) | .3490 |
| Cholesterol level, mg/dL (SD) | 157 (58) | 188 (45) | .0157 |
| Treatment at registration (%) | |||
| Phlebotomy | 13 (59.09) | 1027 (63.55) | .6660 |
| P32 | 3 (13.64) | 41 (2.54) | .0014 |
| Hydroxyurea | 10 (45.45) | 783 (48.45) | .7798 |
| Busulphan | 4 (18.18) | 57 (3.53) | .0003 |
| Chlorambucil | 0 (0.00) | 5 (0.31) | .7939 |
| Pipobroman | 4 (18.18) | 102 (6.31) | .0246 |
| Interferon | 1 (4.55) | 63 (3.90) | .8764 |
| Groups of treatment at registration (%) | |||
| No treatment, phlebotomy only, or interferon only | 5 (22.73) | 664 (41.09) | .0818 |
| Hydroxyurea as only cytoreductive drug | 6 (27.27) | 736 (45.54) | .0873 |
| Any other cytoreductive drug, alone or in combination | 11 (50.00) | 216 (13.37) | < .0001 |
| More than 1 cytoreductive drug | 4 (18.18) | 54 (3.34) | .0002 |
| Event at follow-up (%) | |||
| Thrombosis | 5 (22.73) | 226 (13.99) | .2419 |
| Hemorrhage | 4 (18.18) | 117 (7.24) | .0513 |